MARROW TRANSPLANTATION FOR MYELOMA
- 1 February 1995
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 46 (1) , 299-307
- https://doi.org/10.1146/annurev.med.46.1.299
Abstract
▪ Abstract High-dose therapy with hemopoietic stem cell support in multiple myeloma (MM) has been used for 10 years. This approach is currently the most promising form of treatment for this disease. We review here its rationale and the results of clinical trials according to the source of hematopoietic stem cells [allogeneic or autologous, bone marrow or blood]. Finally, we discuss the ongoing uncertainties regarding the utility of this treatment and the future prospects for high-dose therapy in MM.Keywords
This publication has 10 references indexed in Scilit:
- Limited value of myeloablative therapy for late multiple myelomaBlood, 1994
- Monoclonal antibody-purged bone marrow transplantation therapy for multiple myelomaBlood, 1993
- High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patientsBlood, 1993
- Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trialBlood, 1993
- Double-intensive therapy in high-risk multiple myelomaBlood, 1992
- Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factorsBlood, 1990
- Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graftBlood, 1989
- High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myelomaBlood, 1987
- Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow TransplantationBlood, 1987
- High-dose melphalan with autologous bone marrow transplantation for multiple myelomaBlood, 1986